Lichen planus treatment focuses on controlling symptoms, reducing inflammation, and preventing complications. While many cases clear on their own within months to years, effective therapies can ease discomfort and improve quality of life during flare-ups.

How Medical Experts Approach Lichen Planus Care

When someone develops lichen planus, the main goals of treatment revolve around managing symptoms rather than curing the condition outright. The approach depends heavily on where the rash appears, how widespread it is, and how much discomfort it causes. Some people experience only mild itching and small patches of discolored skin, while others face painful mouth sores or extensive body rashes that significantly interfere with daily activities^[1].

The stage and severity of the condition play a crucial role in determining the treatment path. A patient with just a few purple bumps on the wrist might need only moisturizers and careful skin care, whereas someone with erosive oral lichen planus—where painful ulcers develop inside the mouth—may require stronger prescription medications and ongoing monitoring^[2]. The location matters enormously: skin lesions typically heal faster than those affecting mucous membranes like the mouth or genitals.

Medical societies and clinical guidelines recognize that there are standard, well-established treatments proven to help most patients. At the same time, researchers continue investigating new therapies through clinical trials, seeking better options for those who don’t respond to conventional approaches or who experience severe, persistent forms of the disease^[3]. The good news is that most people with skin-only lichen planus see their condition resolve spontaneously within one to two years, though recurrences are common and residual darkening of the skin often lingers longer^[6].

Standard Treatment Options That Doctors Prescribe

The cornerstone of lichen planus treatment involves medications called corticosteroids, which are powerful anti-inflammatory drugs that calm down the immune system’s overactive response. These come in several forms depending on the severity and location of the rash. For most people with skin lesions, high-potency topical corticosteroid creams or ointments serve as the first line of defense. Medications like clobetasol propionate are applied directly to affected areas to reduce redness, swelling, and the intense itching that characterizes this condition^[6].

These topical steroids work by suppressing inflammation in the skin layers where the immune cells are attacking. Patients typically apply them once or twice daily to the purple, flat-topped bumps that define lichen planus. The treatment duration varies—some people need only a few weeks, while others require months of application, especially if the lesions are thick or resistant. The goal is to use the lowest effective dose for the shortest time necessary, as prolonged use of strong topical steroids can thin the skin^[9].

When the rash covers large areas of the body or proves resistant to creams, doctors may prescribe oral corticosteroids like prednisone. A typical course starts with 30 to 60 milligrams per day, gradually tapering over three to six weeks. This systemic approach delivers medication throughout the entire body, making it effective for widespread disease. However, oral steroids carry more significant side effects than topical forms, including weight gain, mood changes, elevated blood sugar, and weakened bones with long-term use^[11].

For thickened, raised lesions called hypertrophic lichen planus—which often appear on the shins and ankles—doctors sometimes inject corticosteroids directly into the lesions. A medication called triamcinolone acetonide at concentrations of 5 to 10 milligrams per milliliter can be injected into stubborn plaques every few weeks. This delivers high concentrations of steroid precisely where needed without systemic side effects^[6].

Beyond corticosteroids, several other medications play supporting roles. The antimalarial drug hydroxychloroquine (Plaquenil) is sometimes prescribed for lichen planus, particularly when it affects the mouth or skin extensively. Originally developed to treat malaria and later used for autoimmune conditions like lupus, this medication helps modulate the immune system. Similarly, the antibiotic metronidazole and the antifungal griseofulvin have been tried, though evidence for their effectiveness is limited^[9].

For oral and genital lichen planus, another class of medications called calcineurin inhibitors serves as a second-line option. These include tacrolimus (Protopic) and pimecrolimus (Elidel), which were originally developed for eczema. They work by blocking specific immune system signals that drive inflammation. Applied as ointments to delicate mucous membrane tissues, they avoid some of the side effects associated with long-term steroid use in sensitive areas like the mouth and genitals^[6].

An interesting alternative that has shown benefit for oral lichen planus is the antibiotic doxycycline. Doctors often start patients at 50 to 100 milligrams twice daily for several months, then reduce to lower “sub-antimicrobial” doses of 20 to 40 milligrams daily for maintenance. Beyond fighting bacteria, doxycycline has anti-inflammatory properties that can reduce the painful erosions and burning sensations in the mouth^[19].

The duration of treatment depends on the body site affected and individual response. Skin lesions may need treatment for weeks to months before clearing, while oral lesions often require longer therapy and may need intermittent treatment for years. Clinical guidelines emphasize that asymptomatic disease shouldn’t be overtreated—the potential harms from chronic medication use can exceed the benefits when patients aren’t suffering^[12].

Side effects vary by medication type and delivery method. Topical corticosteroids can cause skin thinning, stretch marks, and changes in skin color with prolonged use. Oral corticosteroids carry broader risks including high blood pressure, diabetes, cataracts, and increased infection susceptibility. Hydroxychloroquine requires periodic eye examinations because it can rarely affect the retina. Calcineurin inhibitors may cause burning or stinging at application sites, and there’s been concern about a theoretical cancer risk with long-term use, though this hasn’t been clearly established^[17].

Treatment Approaches Being Tested in Clinical Trials

Because standard treatments don’t work for everyone and oral lichen planus can persist for years despite therapy, researchers are actively investigating new approaches through clinical studies. These trials test promising medications that haven’t yet received approval specifically for lichen planus but show potential based on their mechanisms of action and early results^[8].

One class of drugs generating interest involves oral retinoids—compounds related to vitamin A that affect how skin cells grow and differentiate. Acitretin and isotretinoin (better known for treating severe acne) have the most evidence for treating moderate to severe lichen planus. These medications appear to help the immune system reset its response and normalize the excessive inflammation. Acitretin typically works better for lichen planus overall, though isotretinoin offers advantages for women of childbearing age because it clears from the body much faster—within weeks rather than years^[19].

Doctors usually start isotretinoin at 0.5 milligrams per kilogram of body weight daily—considerably lower than doses used for acne. Acitretin typically begins at 17.5 to 20 milligrams daily and can be adjusted based on response. These are Phase III trials, meaning researchers are comparing these treatments against standard approaches in larger patient groups to confirm effectiveness and safety. The medications must be used cautiously in women who could become pregnant because they cause severe birth defects. Common side effects include dry lips and skin, sensitivity to sunlight, and changes in blood cholesterol levels^[8].

Apremilast (Otezla) represents another investigational option currently in clinical trials. This medication, already approved for psoriasis and psoriatic arthritis, belongs to a class called phosphodiesterase-4 (PDE4) inhibitors. It works by blocking certain enzymes inside immune cells, reducing production of inflammatory molecules. Small studies have shown that apremilast can help manage moderate to severe lichen planus, though the results weren’t dramatic. Still, it offers an accessible option with generally tolerable side effects—mainly nausea, diarrhea, and headache—for a disease with limited approved treatments^[19].

Perhaps most exciting are trials investigating biologic medications that target specific parts of the immune system. Research suggests that lichen planus involves overproduction of an immune signaling molecule called interleukin-17 (IL-17), which drives inflammation. Biologics that block IL-17 or its receptor have shown promise in early studies. Secukinumab (Cosentyx) and ixekizumab (Taltz), both antibody medications given by injection, have been tested in patients with lichen planus affecting skin and nails. These drugs work by neutralizing IL-17, preventing it from triggering the inflammatory cascade that damages skin^[19].

These are still early-phase trials—mostly Phase II studies examining effectiveness in small patient groups—but preliminary results appear encouraging. Some dermatologists report success treating both widespread skin disease and the difficult-to-treat nail involvement that can cause permanent damage. The biologics are generally well-tolerated, with the main concerns being increased infection risk and injection site reactions. They require regular injections—typically monthly after initial loading doses^[19].

The mechanisms behind these experimental treatments vary. Retinoids influence gene expression in skin cells and immune cells, helping normalize the excessive keratinocyte death that characterizes lichen planus. PDE4 inhibitors reduce levels of inflammatory molecules called cytokines within immune cells. Biologics neutralize specific cytokines like IL-17 that drive the autoimmune attack on skin proteins. By targeting different parts of the disease process, these treatments offer hope for patients who don’t respond to conventional corticosteroids^[8].

Preliminary trial results have shown improvements in various clinical parameters. In studies with retinoids, researchers report reductions in lesion size, decreased itching intensity, and fewer new lesions developing. Apremilast trials have demonstrated modest improvements in rash severity scores and quality-of-life measures. Biologic studies report clearing or significant improvement of both skin plaques and nail changes in some patients, with generally positive safety profiles during the trial periods^[19].

Patient eligibility for these trials typically requires a confirmed diagnosis through skin biopsy showing the characteristic pattern of lichen planus. Many trials seek patients with moderate to severe disease who haven’t responded adequately to at least one conventional treatment. Exclusion criteria often include pregnancy, serious infections, certain other autoimmune conditions, and compromised immune systems. Trial locations span multiple countries, with studies ongoing in the United States, various European nations, and other regions where research institutions have dermatology trial programs^[8].

Most common treatment methods

• Topical corticosteroids
  • High-potency steroid creams and ointments like clobetasol propionate applied directly to skin lesions
  • First-line treatment for cutaneous, genital, and mucosal erosive lesions
  • Reduce inflammation, itching, and halt disease progression
  • Applied once or twice daily for weeks to months depending on response
• Systemic corticosteroids
  • Oral prednisone typically starting at 30 to 60 mg daily with gradual tapering over 3 to 6 weeks
  • Used for severe, widespread disease affecting oral, cutaneous, or genital sites
  • Intralesional triamcinolone acetonide injections (5 to 10 mg per mL) for hypertrophic lesions
• Calcineurin inhibitors
  • Topical tacrolimus and pimecrolimus used as second-line therapy
  • Particularly effective for genital and oral lichen planus
  • Block immune signals that drive inflammation in sensitive mucosal tissues
• Antimalarial and antibiotic medications
  • Hydroxychloroquine (Plaquenil) for oral and cutaneous disease
  • Doxycycline 50 to 100 mg twice daily for oral lichen planus, with anti-inflammatory effects beyond antimicrobial action
  • Metronidazole and griseofulvin tried with limited evidence
• Investigational retinoids
  • Oral acitretin starting at 17.5 to 20 mg daily for moderate to severe disease
  • Isotretinoin at 0.5 mg/kg body weight as alternative, particularly for women of childbearing potential
  • Best evidence among systemic treatments in clinical trials
• Novel immunomodulators in trials
  • Apremilast (Otezla), a PDE4 inhibitor, showing modest benefit in small studies
  • IL-17 biologics including secukinumab (Cosentyx) and ixekizumab (Taltz) for cutaneous and nail disease
  • Emerging evidence targeting Th17 pathway dysfunction